コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 h gadoxetate disodium and 204 performed with gadobenate dimeglumine.
2 gnificantly more often than with intravenous gadobenate dimeglumine.
3 ol/L gadopentetate dimeglumine and 0.5 mol/L gadobenate dimeglumine.
4 = 97; 8 mL, n = 1; 16 mL, n = 1] and 99 with gadobenate dimeglumine [0.1 mmol per kilogram of body we
5 gher rate with gadoxetate disodium than with gadobenate dimeglumine (10.7% [37 of 345 examinations] v
6 fter gadoxetate disodium administration than gadobenate dimeglumine (14% [14 of 99] vs 5% [five of 99
7 etate disodium, 16.6 mL vs 16.6 mL, P = .99; gadobenate dimeglumine, 18.0 mL vs 17.8 mL, P = .77) and
8 ratory motion-related artifact compared with gadobenate dimeglumine (39% vs 10%, P < .0001) and of ne
10 graphy (0.2 mmol per kilogram of body weight gadobenate dimeglumine administered at a rate of 2.0 mL
11 ailure developed NSF after administration of gadobenate dimeglumine after more than 2 years' mean fol
13 Following the switch from gadodiamide to gadobenate dimeglumine and gadopentetate dimeglumine, an
14 ant difference of 3.1 msec was noted between gadobenate dimeglumine and placebo (95% CI: -1.8, 8.0) a
16 ically approved Gd chelate, Multihance((R)) (gadobenate dimeglumine), and a novel experimental liposo
17 contrast agents (gadopentetate dimeglumine, gadobenate dimeglumine, and gadofosveset trisodium) dilu
20 nificantly (P <.05) superior enhancement for gadobenate dimeglumine compared with that for gadopentet
21 g brain tumors was achieved with 0.1 mmol/kg gadobenate dimeglumine compared with that with 0.1 mmol/
22 tration of the linear agents gadodiamide and gadobenate dimeglumine compared with the macrocyclic age
26 le gadodiamide-enhanced studies but not with gadobenate dimeglumine-enhanced studies, likely reflecti
27 SI was found between half-dose and full-dose gadobenate dimeglumine-enhanced synovial tissue (mean: 9
28 e data sets for gadoxetate disodium than for gadobenate dimeglumine for both the general population (
29 synthesis was stimulated by gadoversetamide, gadobenate dimeglumine, gadodiamide, and gadopentetate d
32 d occurs significantly more often than after gadobenate dimeglumine in patients who received both con
33 ium per gram of tissue (95% CI: 3.5, 6.1) in gadobenate dimeglumine-injected rats, and 6.9 mug gadoli
34 re noted in seven of 47 (15%) subjects after gadobenate dimeglumine injection and in five of 47 (11%)
38 oversetamide, gadopentetate dimeglumine, and gadobenate dimeglumine) produced a maximum stimulation o
40 suggest gadolinium deposition in the DN with gadobenate dimeglumine use, although it is considerably
43 and the on-site investigators, respectively, gadobenate dimeglumine was preferred in 13, 17, and 16 p
44 assessed 2 years before and 3.5 years after gadobenate dimeglumine was substituted for gadopentetate
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。